Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION Time Ripe for Debate on Drug Spending Macroeconomic Indexing: INES
June 3, 2026
-
BUSINESS AbbVie Japan Says Sales-Doubling Plan on Track as Revenue Climbs 13.5%
June 3, 2026
-
ACADEMIA Tavneos Data Integrity Issue Could Spill Over to Japan, Investigator Warns
June 2, 2026
-
REGULATORY Novo’s Wegovy Nears Japan Approval as First MASH Therapy
June 1, 2026
-
BUSINESS Eylea Bio-AG Snags 60% Share in Just 3 Months, Outpacing Biosimilar
May 29, 2026
-
ORGANIZATION Global Pharma CEOs Urge Japan PM to Boost Support for Innovative Drugs
May 29, 2026
-
BUSINESS Bayer Regulatory Chief Hails Japan’s Review System, Flexibility on PI Waivers
May 28, 2026
-
BUSINESS Astellas Sees Sales Decline through FY2029 on Xtandi LOE, Maps 200 Billion Yen Cuts in 5 Years
May 27, 2026
-
REGULATORY LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
May 27, 2026
-
REGULATORY US Calls Out Japan’s Market Expansion Re-Pricing Rules as “Unfair”: IP Report
May 26, 2026
-
COMMENTARY Are Technical Discussions Enough for Japan’s CEA System?
May 25, 2026
-
BUSINESS Japan Market Hits Record 11.8 Trillion Yen in FY2025, Keytruda Keeps Title: IQVIA
May 22, 2026
-
BUSINESS Kissei Drops Call to Halt New Tavneos Use after Blue Letter Action
May 22, 2026
-
REGULATORY Update: Tavneos Slapped with Blue Letter Action in Japan over Liver Injury Risk
May 22, 2026
-
ORGANIZATION Novartis’ Pullicino to Helm EFPIA Japan from July
May 22, 2026
-
BUSINESS BMS, Nikon Pitch Japan-to-Asia Cell Therapy Push, Draw Support at Policy Forum
May 21, 2026
-
BUSINESS Sanofi Eyes Double-Digit Annual Growth for Japan Vaccine Business: Exec
May 20, 2026
-
REGULATORY Japan to Start CEA Technical Discussions as Early as May 25
May 20, 2026
-
REGULATORY Japan Approves Jascayd, mNEXSPIKE, Zepbound OSA Use, Others
May 19, 2026
-
REGULATORY Wegovy’s MASH Label Expansion and More Up for Japan Panel Review on May 29
May 18, 2026
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…